Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLC5508 combination therapy in advanced solid tumors
ChiCTR2500110587Phase 2Not yet recruiting
- Sponsor
- Shanghai East Hospital
- Start
- Oct 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MHB088C in Nonhematologic neoplasms (6 arms), sponsored by Shanghai East Hospital. Primary endpoints: Maximum tolerated dose, Maximum administered dose and 2 more. Planned start Oct 2025; status: not yet recruiting.
02
Drugs
MHB088C
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR2500110587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500110587.